Therapies for HIV infection and cancer have evolved exponentially during the past 20 plus years. The year 1996 marked the availability of 3-drug combination antiretroviral therapy (ART); in 1997, rituximab was approved as the first monoclonal antibody for the treatment of cancer. Despite advances in both fields during the ensuing decades, a question remains as to whether we are optimizing meaningful therapeutic advances for people living with HIV and cancer. Treatment of HIV-associated malignant neoplasms underwent a major paradigm shift with the introduction of ART. Before effective HIV therapy, many cancer treatment regimens in people living with HIV were dose reduced and largely palliative. However, availability of ART and associated immune reconstitution led to a series of studies that demonstrated that many people living with HIV were able to tolerate standard cancer therapies and, with the exception of those with very low CD4 counts (eg, <50-100 cells/μL), often had outcomes comparable to those of the general population. Despite improved cancer outcomes, many early ARTs had toxic effects that overlapped with cancer therapies. Furthermore, an important class of ART, protease inhibitors, has clinically significant CYP3A4-mediated drug-drug interactions that may increase the toxic effects of many common antineoplastic agents.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bender Ignacio R, Ddungu H, Uldrick TS. Untangling the Effects of Chemotherapy and HIV on CD4 Counts—Implications for Immunotherapy in HIV and Cancer. JAMA Oncol. 2020;6(2):235–236. doi:10.1001/jamaoncol.2019.4634
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: